{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:08:05Z","timestamp":1794049685245,"version":"4.8.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuropharm.2025.110622","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:49:33Z","timestamp":1753976973000},"page":"110622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases"],"prefix":"10.1016","volume":"279","author":[{"given":"Monika","family":"Fryc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Kluzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Czopek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Jo\u0144czyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7237","authenticated-orcid":false,"given":"Agnieszka","family":"Zag\u00f3rska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acsptsci.1c00018","article-title":"Naturalistic use of mescaline is associated with self-reported psychiatric improvements and enduring positive life changes","volume":"4","author":"Agin-Liebes","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2025.110622_bib2","article-title":"Long-term outcomes with pimavanserin for psychosis in clinical practice","volume":"6","author":"Akbar","year":"2022","journal-title":"Clin. Park.; Relat. Disord."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110622_bib3","doi-asserted-by":"crossref","first-page":"9831","DOI":"10.1021\/acs.jmedchem.5c01156","article-title":"Targeting the 5-HT2A receptor for developing psychedelic drugs and beyond","volume":"68","author":"Ali","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JAD-231167","article-title":"Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a phase 3B study","volume":"98","author":"Alva","year":"2024","journal-title":"J. Alzheim. Dis. : JAD"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110622_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00424-015-1780-7","article-title":"Cross-signaling in metabotropic glutamate 2 and serotonin 2A receptor heteromers in mammalian cells","volume":"468","author":"Baki","year":"2016","journal-title":"Pflueg. Arch. Eur. J. Physiol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110622_bib7","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/gps.5381","article-title":"Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: a post hoc analysis","volume":"35","author":"Ballard","year":"2020","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110622_bib8","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1038\/d41586-022-02873-8","article-title":"Finding medical value in mescaline","volume":"609","author":"Bender","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110622_bib9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/mdc3.13207","article-title":"Pilot study to evaluate pimavanserin for the treatment of motor and behavioral symptoms of tourette syndrome","volume":"8","author":"Billnitzer","year":"2021","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110622_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"issue":"4\u20135","key":"10.1016\/j.neuropharm.2025.110622_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0028-3908(97)00049-X","article-title":"RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist","volume":"36","author":"Bonhaus","year":"1997","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","article-title":"Regulation of human research with LSD in the United States (1949-1987)","volume":"235","author":"Bonson","year":"2018","journal-title":"Psychopharmacology"},{"issue":"7562","key":"10.1016\/j.neuropharm.2025.110622_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nature14659","article-title":"Sparse whole-genome sequencing identifies two loci for major depressive disorder","volume":"523","author":"Cai","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110622_bib14","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1124\/jpet.113.208637","article-title":"Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands","volume":"347","author":"Canal","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"19","key":"10.1016\/j.neuropharm.2025.110622_bib16","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1016\/j.neuron.2022.08.006","article-title":"Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD","volume":"110","author":"Cao","year":"2022","journal-title":"Neuron"},{"issue":"6579","key":"10.1016\/j.neuropharm.2025.110622_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2025.110622_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","article-title":"Neuropharmacology of N,N-dimethyltryptamine","volume":"126","author":"Carbonaro","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110622_bib19","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110622_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115028","article-title":"\u201cSelective\u201d serotonin 5-HT2A receptor antagonists","volume":"200","author":"Casey","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110622_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"19","key":"10.1016\/j.neuropharm.2025.110622_bib22","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1073\/pnas.86.19.7321","article-title":"Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins","volume":"86","author":"Costa","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acschemneuro.2c00597","article-title":"Pharmacological mechanism of the non-hallucinogenic 5-HT2AAgonist Ariadne and analogs","volume":"14","author":"Cunningham","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/jpet.107.135046","article-title":"Transglutaminase-catalyzed transamidation: a novel mechanism for Rac1 activation by 5-hydroxytryptamine2A receptor stimulation","volume":"326","author":"Dai","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110622_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110622_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cne.20082","article-title":"The 5-HT2A receptor is widely distributed in the rat spinal cord and mainly localized at the plasma membrane of postsynaptic neurons","volume":"472","author":"Doly","year":"2004","journal-title":"J. Comp. Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1021\/acs.chemrev.3c00375","article-title":"Serotonin 2A receptor (5-HT2AR) agonists: psychedelics and non-hallucinogenic analogues as emerging antidepressants","volume":"124","author":"Duan","year":"2024","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110622_bib29","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/med.22042","article-title":"Beyond dopamine: novel strategies for schizophrenia treatment","volume":"44","author":"Dudzik","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib30","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1021\/acs.jmedchem.9b01404","article-title":"Identification of psychoplastogenic N, N-dimethylaminoisotryptamine (isoDMT) analogues through structure-activity relationship studies","volume":"63","author":"Dunlap","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/NDT.S5700","article-title":"Brain-derived neurotrophic factor: role in depression and suicide","volume":"5","author":"Dwivedi","year":"2009","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2025.110622_bib32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jep.2005.04.022","article-title":"Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas","volume":"101","author":"El-Seedi","year":"2005","journal-title":"J. Ethnopharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110622_bib33","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jcbfm.2014.68","article-title":"Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36","volume":"34","author":"Ettrup","year":"2014","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110622_bib34","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12928","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY)","volume":"80","author":"Fava","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110622_bib35","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1073\/pnas.87.6.2187","article-title":"Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis","volume":"87","author":"Felder","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110622_bib36","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00435.2001","article-title":"5-HT(2A) receptors: location and functional analysis in intestines of wild-type and 5-HT(2A) knockout mice","volume":"282","author":"Fiorica-Howells","year":"2002","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110622_bib37","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/cercor\/bhp022","article-title":"Medial prefrontal cortex 5-HT2A density is correlated with amygdala reactivity, response habituation, and functional coupling","volume":"19","author":"Fisher","year":"2009","journal-title":"Cerebr. Cortex"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110622_bib38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF00165548","article-title":"Allosteric properties of the 5-HT2 receptor system of the rat tail artery: ritanserin and methysergide are not competitive 5-HT2 receptor antagonists but allosteric modulators","volume":"335","author":"Frenken","year":"1987","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.neuropharm.2025.110622_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic use of LSD in psychiatry: a systematic review of randomized-controlled clinical trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front. Psychiatr."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110622_bib40","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.euroneuro.2019.10.013","article-title":"Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: selective biased agonism via G\u03b1i1-proteins","volume":"29","author":"Garc\u00eda-Bea","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110622_bib41","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41380-024-02724-0","article-title":"Molecular and micro-architectural mapping of gray matter alterations in psychosis","volume":"30","author":"Garc\u00eda-San-Mart\u00edn","year":"2025","journal-title":"Mol. Psychiatr."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110622_bib42","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1517\/14656566.3.12.1773","article-title":"Aripiprazole: profile on efficacy and safety","volume":"3","author":"Goodnick","year":"2002","journal-title":"Expet Opin. Pharmacother."},{"issue":"18","key":"10.1016\/j.neuropharm.2025.110622_bib43","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-199448020-00009","article-title":"Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia","volume":"48","author":"Grant","year":"1994","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110622_bib45","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0361-9230(01)00623-2","article-title":"Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists","volume":"56","author":"Gray","year":"2001","journal-title":"Brain Res. Bull."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110622_bib46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ijnp\/pyab085","article-title":"Psilocybin therapy of psychiatric disorders is not hampered by hERG potassium channel\u2013mediated cardiotoxicity","volume":"25","author":"Hackl","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110622_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1017\/S0033291721004207","article-title":"Why was early therapeutic research on psychedelic drugs abandoned?","volume":"52","author":"Hall","year":"2022","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195","author":"Hannon","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1212\/CPJ.0000000000000342","article-title":"Pimavanserin: a novel therapeutic option for Parkinson disease psychosis","volume":"7","author":"Hawkins","year":"2017","journal-title":"Neurology. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2025.110622_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109610","article-title":"Psychedelics: threshold of a therapeutic revolution","volume":"236","author":"Heal","year":"2023","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110622_bib52","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib54","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41593-018-0326-7","article-title":"Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions","volume":"22","author":"Howard","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110622_bib56","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/ng.3623","article-title":"Identification of 15 genetic loci associated with risk of major depression in individuals of European descent","volume":"48","author":"Hyde","year":"2016","journal-title":"Nat. Genet."},{"issue":"15","key":"10.1016\/j.neuropharm.2025.110622_bib57","first-page":"2384","article-title":"Serotonin receptor 5-HT2A regulates TrkB receptor function in heteroreceptor complexes","volume":"11","author":"Ilchibaeva","year":"2022","journal-title":"Cells 2022"},{"issue":"10323","key":"10.1016\/j.neuropharm.2025.110622_bib58","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(21)01730-X","article-title":"Schizophrenia","volume":"399","author":"Jauhar","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib59","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia","volume":"156","author":"Kapur","year":"1999","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib60","first-page":"598","article-title":"Inverse, protean, and ligand-selective agonism: matters of receptor conformation","volume":"15","author":"Kenakin","year":"2001","journal-title":"FASEB (Fed. Am. Soc. Exp. Biol.) J. : Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib61","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/mol.65.1.2","article-title":"Efficacy as a vector: the relative prevalence and paucity of inverse agonism","volume":"65","author":"Kenakin","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib62","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41594-018-0180-z","article-title":"Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine","volume":"26","author":"Kimura","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib63","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41398-024-03116-2","article-title":"Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects","volume":"14","author":"Klaiber","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-024-48196-2","article-title":"G protein-specific mechanisms in the serotonin 5-HT2A receptor regulate psychosis-related effects and memory deficits","volume":"15","author":"Kossatz","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110622_bib65","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.1471-4159.2003.01921.x","article-title":"A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases","volume":"86","author":"Kurrasch-Orbaugh","year":"2003","journal-title":"J. Neurochem."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110622_bib66","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112203","article-title":"A non-hallucinogenic LSD analog with therapeutic potential for mood disorders","volume":"42","author":"Lewis","year":"2023","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110622_bib68","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib69","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3565(25)13416-2","article-title":"Biochemical profile of risperidone, a new antipsychotic","volume":"247","author":"Leysen","year":"1988","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110622_bib70","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/jm401958n","article-title":"Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110622_bib71","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/WNL.31.8.961","article-title":"Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa","volume":"31","author":"Lieberman","year":"1981","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110622_bib72","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial","volume":"79","author":"Lieberman","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110622_bib73","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110622_bib74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways","volume":"36","author":"L\u00f3pez-Gim\u00e9nez","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110622_bib75","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib76","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.114.213819","article-title":"Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110622_bib77","first-page":"685","article-title":"Serotonergic signaling: multiple effectors and pleiotropic effects","volume":"1","author":"Masson","year":"2012","journal-title":"Wiley Interdiscip. Rev.: Membr. Transport Signal."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib78","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.neuroscience.2007.01.047","article-title":"Neuronal localization of 5-ht2a receptor immunoreactivity in the rat basolateral amygdala","volume":"146","author":"McDonald","year":"2007","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib79","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry : Off. J. World Psychiatr. Assoc. (WPA)"},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2025.110622_bib80","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2012.07.029","article-title":"Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg\/day, but does not enhance efficacy of haloperidol, 2mg\/day: comparison with reference dose risperidone, 6mg\/day","volume":"141","author":"Meltzer","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuropharm.2025.110622_bib81","author":"Meltzer"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib82","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41386-021-01188-y","article-title":"The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity","volume":"47","author":"Millard","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110622_bib83","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110622_bib84","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41386-023-01772-4","article-title":"Greater subjective effects of a low dose of LSD in participants with depressed mood","volume":"49","author":"Molla","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110622_bib85","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.euroneuro.2012.10.006","article-title":"Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects","volume":"23","author":"Muguruza","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110622_bib86","article-title":"Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: a randomized trial","author":"M\u00fcller","year":"2025","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.neuropharm.2025.110622_bib87","article-title":"Ligand bias and inverse agonism on 5-HT2A receptor-mediated modulation of G protein activity in post-mortem human brain","author":"Muneta-Arrate","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib88","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2004.08.005","article-title":"Functions of 5-HT2A receptor and its antagonists in the cardiovascular system","volume":"104","author":"Nagatomo","year":"2004","journal-title":"Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40359-025-02449-x","article-title":"The medial prefrontal cortex as a proposed regulatory structure in the relationship between anxiety and perceived social support: a review","volume":"13","author":"Navarro-Nolasco","year":"2025","journal-title":"BMC Psychol."},{"key":"10.1016\/j.neuropharm.2025.110622_bib90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.brainres.2015.12.042","article-title":"Serotonin receptors in brain revisited","volume":"1645","author":"Palacios","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110622_bib91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/psyrad\/kkae015","article-title":"Neurostructural changes in schizophrenia and treatment-resistance: a narrative review","volume":"4","author":"Paul","year":"2024","journal-title":"Psychoradiology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib92","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00441-018-2978-8","article-title":"Monoaminergic system and depression","volume":"377","author":"Perez-Caballero","year":"2019","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2025.110622_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1217102","article-title":"Keeping the promise: a critique of the current state of microdosing research","volume":"15","author":"Petranker","year":"2024","journal-title":"Front. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib94","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.npp.1301574","article-title":"Stress, depression, and neuroplasticity: a convergence of mechanisms","volume":"33","author":"Pittenger","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110622_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1233743","article-title":"The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice","volume":"10","author":"Pogorelov","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110622_bib96","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/02698811241254831","article-title":"Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research","volume":"38","author":"Polito","year":"2024","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110622_bib98","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.neuropharm.2025.110622_bib99","first-page":"123","article-title":"Serotonin 2A (5-HT2A) receptor function: ligand-dependent mechanisms and pathways","author":"Raote","year":"2007","journal-title":"Serotonin Recept. Neurobiol."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110622_bib100","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.biopsych.2024.02.192","article-title":"14. Preclinical pharmacology of DLX-001, a novel non-hallucinogenic neuroplastogen with the potential for treating neuropsychiatric diseases","volume":"95","author":"Rasmussen","year":"2024","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009019","article-title":"Psychedelics and the human receptorome","volume":"5","author":"Ray","year":"2010","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110622_bib102","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110622_bib103","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110622_bib104","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol. : J. Europa. College Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-01811-4","article-title":"Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers","volume":"11","author":"Rootman","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib106","first-page":"1","article-title":"Positive symptoms of schizophrenia and their relationship with cognitive and emotional executive functions","volume":"7","author":"Ruiz-Casta\u00f1eda","year":"2022","journal-title":"Cognit. Res.: Princ. Impli."},{"issue":"25","key":"10.1016\/j.neuropharm.2025.110622_bib107","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/0024-3205(95)00210-W","article-title":"The role of 5-HT2A receptors in antipsychotic activity","volume":"56","author":"Schmidt","year":"1995","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib108","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00702-022-02567-5","article-title":"Neurodevelopmental disturbances in schizophrenia: evidence from genetic and environmental factors","volume":"130","author":"Schmitt","year":"2023","journal-title":"J. Neural Transm."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110622_bib109","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, A novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110622_bib110","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.tibs.2011.06.003","article-title":"Emerging paradigms of \u03b2-arrestin-dependent seven transmembrane receptor signaling","volume":"36","author":"Shukla","year":"2011","journal-title":"Trends Biochem. Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib111","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0888-7543(91)90411-7","article-title":"Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14\u2013q21 and mouse chromosome 14","volume":"9","author":"Sparkes","year":"1991","journal-title":"Genomics"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110622_bib112","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.tips.2008.03.009","article-title":"Antipsychotic drug action: antagonism, inverse agonism or partial agonism","volume":"29","author":"Strange","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"26","key":"10.1016\/j.neuropharm.2025.110622_bib113","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.2174\/1381612821666150605111236","article-title":"Atypical antipsychotics and inverse agonism at 5-HT2 receptors","volume":"21","author":"Sullivan","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110622_bib114","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of pimavanserin in dementia-related psychosis","volume":"385","author":"Tariot","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2025.110622_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1391689","article-title":"In vitro and in vivo metabolism of psilocybin's active metabolite psilocin","volume":"15","author":"Thomann","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib116","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin--summary of knowledge and new perspectives","volume":"24","author":"Tyl\u0161","year":"2014","journal-title":"Eur. Neuropsychopharmacol. : J. Europa. College Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2007","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110622_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109294","article-title":"Mescaline: the forgotten psychedelic","volume":"222","author":"Vamvakopoulou","year":"2023","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110622_bib119","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1039\/D4MD00043A","article-title":"Synthesis and bioactivity of psilocybin analogues containing a stable carbon\u2013phosphorus bond","volume":"15","author":"Vandevelde","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110622_bib120","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2019-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"6633","key":"10.1016\/j.neuropharm.2025.110622_bib121","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","author":"Vargas","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential","volume":"14","author":"Wallach","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FBP.0000000000000183","article-title":"5-HT2A and mGlu2\/3 receptor interactions: on their relevance to cognitive function and psychosis","volume":"27","author":"Wischhof","year":"2016","journal-title":"Behav. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110622_bib124","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.40.4.228","article-title":"A biochemical and pharmacological suggestion about certain mental disorders","volume":"40","author":"Woolley","year":"1954","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110622_bib125","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41588-018-0090-3","article-title":"Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression","volume":"50","author":"Wray","year":"2018","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110622_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-022-02233-0","article-title":"The interplay of dopamine metabolism abnormalities and mitochondrial defects in the pathogenesis of schizophrenia","volume":"12","author":"Xu","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110622_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00087","article-title":"Pimavanserin: a novel antipsychotic with potentials to address an unmet need of older adults with dementia-related psychosis","volume":"11","author":"Yunusa","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110622_bib128","article-title":"Post-translational modifications of G protein\u2013coupled receptors revealed by proteomics and structural biology","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Chem."},{"issue":"OCT","key":"10.1016\/j.neuropharm.2025.110622_bib129","first-page":"225","article-title":"The role of serotonin 5-HT2A receptors in memory and cognition","volume":"6","author":"Zhang","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110622_bib130","article-title":"Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:13:18Z","timestamp":1780027998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825003302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":129,"alternative-id":["S0028390825003302"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110622","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110622"}}